Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Integrated Diagnostics Holdings EV-to-EBIT?
Integrated Diagnostics HoldingsLSE:IDHC -5.82%58 EV-to-EBIT is 33.76 as of Aug. 03, 2026, which is 304% above its 10-year median of 8.36. GuruFocus rates LSE:IDHC with a GF Score™ of 58/100 and a GF Value™ of $0.59 (Fairly Valued). The stock has 7 warning signs investors should review. Among 105 Medical Diagnostics & Research companies, Integrated Diagnostics Holdings ranks worse than 70.48% on this metric.
The historical rank and industry rank for Integrated Diagnostics Holdings's EV-to-EBIT or its related term are showing as below:
LSE:IDHC'
s EV-to-EBIT Range Over the Past 10 Years
Min: 2.25 Med: 8.36 Max: 71.85
Current: 33.76
During the past 13 years, the highest EV-to-EBIT of Integrated Diagnostics Holdings was 71.85. The lowest was 2.25. And the median was 8.36.
LSE:IDHC's EV-to-EBIT is ranked worse than 70.48% of 105
companies
in the Medical Diagnostics & Research industry
Industry Median: 23.07
vs LSE:IDHC: 33.76
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Integrated Diagnostics Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was $325.54 Mil.
Integrated Diagnostics Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Diagnostics Holdings EV-to-EBIT Related Terms
Integrated Diagnostics Holdings EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Diagnostics Holdings EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Integrated Diagnostics Holdings's EV-to-EBIT falls into.
Integrated Diagnostics Holdings's current Enterprise Value is $325.44 Mil.
Integrated Diagnostics Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Diagnostics Holdings (LSE:IDHC) has a EV-to-EBIT of 33.76 as of Aug. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Integrated Diagnostics Holdings and its competitors. This is 304% above median its historical median of 8.36. Over the past decade, Integrated Diagnostics Holdings' EV-to-EBIT has ranged from 2.25 to 71.85. According to the industry distribution chart, Integrated Diagnostics Holdings ranks #74 out of 105 companies in the Medical Diagnostics & Research industry, placing it in the top 70.5%.
Is Integrated Diagnostics Holdings' EV-to-EBIT too high?
Integrated Diagnostics Holdings' current EV-to-EBIT of 33.76 is 304% above median its 10-year median of 8.36. Over the past 10 years, this metric has ranged from a low of 2.25 to a high of 71.85. The Medical Diagnostics & Research industry median EV-to-EBIT is 23.07. Integrated Diagnostics Holdings' value of 33.76 is 46.3% above this industry median. Based on the distribution chart, Integrated Diagnostics Holdings ranks #74 out of 105 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Integrated Diagnostics Holdings has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integrated Diagnostics Holdings ranks #74 out of 105 companies for EV-to-EBIT. This places Integrated Diagnostics Holdings in the lower half of its industry. The industry median EV-to-EBIT is 23.07. Integrated Diagnostics Holdings' value of 33.76 is 46.3% above this benchmark. Historically, Integrated Diagnostics Holdings' own EV-to-EBIT has ranged from 2.25 to 71.85 over the past decade. While the company's 10-year median is 8.36 vs. the industry median of 23.07, Integrated Diagnostics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.07, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrated Diagnostics Holdings's current EV-to-EBIT of 33.76 is 46.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Integrated Diagnostics Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Diagnostics Holdings's current EV-to-EBIT is 33.76, which is 304% above median its own 10-year median of 8.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Fairly Valued. The stock's GF Value™ is $0.59, compared to a current price of $0.55 — trading 6.8% below its estimated fair value. The current EV-to-EBIT is 33.76, which is 304% above median its 10-year median of 8.36 and 46.3% above the Medical Diagnostics & Research industry median of 23.07. Integrated Diagnostics Holdings' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current EV-to-EBIT is 33.76 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued.
The current stock price of $0.55 is trading 6.8% below its estimated GF Value™ of $0.59.
GuruFocus considers Integrated Diagnostics Holdings to be Fairly Valued.
Key valuation signals for LSE:IDHC:
EV-to-EBIT: 33.76 (304% above median its 10-year median of 8.36)
GF Value™: $0.59 vs. price of $0.55 (6.8% below fair value)
Industry Position: 46.3% above the Medical Diagnostics & Research median (#74 of 105)
No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
58GF Score
Get the complete analysis for LSE:IDHC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IDHC has been successfully added to your 
